Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Penn Pharma has announced the agreement for the sale of its business to Packaging Coordinators Inc (PCI). This transaction provides a final exit for leading mid-market private equity firm LDC which invested in Penn Pharma in 2007.
Subscribe to our email newsletter
Penn Pharmaceuticals is a UK based global provider of specialist pharmaceutical services providing selected Contract Development and Manufacturing Organisation (CDMO) services to a global customer base to support the outsourcing needs of international customers including those in Europe, the USA and Japan.
As a pharmaceutical manufacturer with specialism in drug development, manufacturing and packaging services the sale will complement US based PCI’s growth in clinical trial and commercial supply services in both North America and Europe.
In recent years, Penn Pharma has invested significantly in its capabilities and capacity. In 2013 Penn opened a new world-class, purpose-built contained manufacturing facility in response to market need for specialist containment solutions for the development and manufacturing of solid dose products containing highly potent compounds. In 2014, Penn launched an additional capacity expansion programme for large-scale commercial manufacturing and packaging operations.
The continued investments made by Penn Pharma and the commitment to quality and customer service has ensured significant growth and has uniquely positioned the company in the specialist outsourcing market helping to grow existing business and drive significant opportunities with new customers.
PCI is a global leader in the packaging services sector. Headquartered in Philadelphia, PA, PCI is a trusted partner to the world’s largest and most successful pharmaceutical firms, offering services from early phase clinical studies through large scale Phase III/IV, commercial launch, and ongoing supply. PCI partners with manufacturers, offering insight and expertise, combined with innovative technologies and an uncompromising commitment to exceptional service and quality.
Commenting on the acquisition, Richard Yarwood, Chief Executive Officer, Penn Pharma said,
"By combining the expertise and resources of PCI and Penn Pharma, we are able to offer exceptional outsourcing solutions to the international healthcare industry. This is a very exciting time, the specialist expertise from Penn together with the experience and global footprint of PCI will provide even more opportunities to support our customers”